Gadobutrol - Bayer HealthCare Pharmaceuticals

Drug Profile

Gadobutrol - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-864875; Gadavist; Gadobutrol injection for MRI of CNS - Bayer; Gadovist; Gadovist 1.0; Gd-DO3A-butriol; SHL 562

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Gadolinium-containing contrast agents; Organometallic compounds; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Vascular disorders
  • Clinical Phase Unknown Brain cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Aug 2017 Bayer completes the phase III GadaCAD 1 trial for Vascular disorders (diagnosis of coronary artery disease) in France, Germany, South Korea, New Zealand, Switzerland, United Kingdom and USA (NCT01890421)
  • 01 Apr 2017 Clinical trials in Brain cancer (Diagnosis) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top